Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125831431 | 12583143 | 1 | I | 20160713 | 20160722 | 20160722 | EXP | NL-AMGEN-NLDSL2016092541 | AMGEN | 0.00 | F | Y | 0.00000 | 20160722 | MD | NL | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125831431 | 12583143 | 1 | PS | ARANESP | DARBEPOETIN ALFA | 1 | Subcutaneous | 150 MUG, (500MCG/ML 0,3ML)Q4WK | U | 103951 | 150 | UG | SOLUTION FOR INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125831431 | 12583143 | 1 | Myelodysplastic syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125831431 | 12583143 | OT |
| 125831431 | 12583143 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125831431 | 12583143 | Bladder disorder | |
| 125831431 | 12583143 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |